Diabetes-specific Formula (DSF) in Individuals With Type 2 Diabetes

NCT ID: NCT05802927

Last Updated: 2023-10-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

64 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-07-05

Study Completion Date

2023-10-26

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A randomized, controlled, crossover design with three treatments to determine the effects of diabetes-specific formula on glycemic control in individuals with type 2 diabetes.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Diabetes Mellitus, Type 2

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Experimental: Diabetes-specific formula

Group Type OTHER

DSF

Intervention Type OTHER

Diabetes-specific formula

Experimental: Breakfast 1 Noodle Soup

Group Type OTHER

Breakfast 1

Intervention Type OTHER

Noodle Soup

Experimental: Breakfast 2 Glutinous rice

Group Type OTHER

Breakfast 2

Intervention Type OTHER

Glutinous rice

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

DSF

Diabetes-specific formula

Intervention Type OTHER

Breakfast 1

Noodle Soup

Intervention Type OTHER

Breakfast 2

Glutinous rice

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Participants are eligible to be included in the study only if all of the following criteria apply:

1. Has type 2 diabetes as evidenced by use of oral antihyperglycemic medication(s).
2. BMI \> 18.5 and ≤ 35.0 kg/m2.
3. Weight stable.
4. Male or non-pregnant, non-lactating female, at least 6 weeks postpartum prior to screening visit.
5. If on chronic medication, the dosage to be constant for at least two months prior to screening visit and to maintain the medication and dose throughout the study.
6. Willing to follow the protocol throughout the study.
7. At least a two-week washout period between completion of a previous research study and their start in the current study.
8. Willing to refrain from taking non-study diabetes-specific formulas over the course of the study.
9. Voluntarily signed and dated an Informed Consent Form (ICF) prior to any participation in the study.

Exclusion Criteria

Participants are excluded from the study if any of the following criteria apply:

1. Has a screening HbA1c level \< 7% or ≥ 10%.
2. Uses exogenous insulin for glucose control.
3. Has confirmed type 1 diabetes and/or had history of diabetic ketoacidosis.
4. Has current infection, inpatient surgery or received systemic corticosteroid treatment in the last 3 months; or received antibiotics in the last 3 weeks.
5. Has active malignancy.
6. Has significant cardiovascular event within 6 months prior to study entry or history of congestive heart failure.
7. Has end stage organ failure or was post organ transplant.
8. Has a history of renal disease or severe gastroparesis.
9. Has current hepatic disease.
10. Has had bariatric surgery including gastric balloon; history of gastrointestinal disease or intestinal surgery that can interfere with consumption or digestion or absorption of study product.
11. Has a chronic, contagious, infectious disease.
12. Has eating disorder, severe dementia or delirium, history of significant neurological or psychiatric disorder, alcoholism, substance abuse or other conditions that may interfere with study product consumption or compliance with study protocol procedures.
13. Taking any herbals, dietary supplements or medications other than allowed anti-hyperglycemic medications, during the past four weeks prior to screening visit that could profoundly affect blood glucose or appetite.
14. Uses diabetes-specific formula(s) defined as more than one eating occasion per week in the last three months.
15. Has clotting or bleeding disorders.
16. Participates in another study that has not been approved as a concomitant study by Abbott Nutrition.
17. Has allergy or intolerance to any ingredient in the study product.
Minimum Eligible Age

21 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Abbott Nutrition

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Agnes Siew Ling Tey, PhD

Role: STUDY_CHAIR

Abbott Nutrition R&D

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Chulalongkorn University

Bangkok, , Thailand

Site Status

Siriraj Hospital

Bangkok, , Thailand

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Thailand

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

BL65

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.